Sign up
Pharma Capital

NetScientific says portfolio company Vortex signs partnership deal with cell imaging firm BioView

The AIM-listed firm said the partnership will enable Vortex and Bioview to create integrated workflows that will allow the collection of intact circulating tumour cells (CTCs) from blood samples to become part of the standard of care
laboratory
BioView is a publicly traded company on the Tel Aviv Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions

NetScientific PLC (LON:NSCI) revealed that its portfolio company Vortex BioSciences has signed a collaboration deal with BioView Ltd, a provider of automated cell imaging and analysis solutions with the aim of providing clinicians with deeper insights into cancer biology.

The AIM-listed transatlantic biomedical and healthcare IP commercialisation group said the partnership will enable Vortex and Bioview to create integrated workflows that will allow the collection of intact circulating tumour cells (CTCs) from blood samples to become part of the standard of care, with a view to increasing the prominence of CTCs in the clinical space as a diagnostic and monitoring tool.

READ: NetScientific announces first sale of point-of-care test from portfolio company

BioView is a publicly traded company on the Tel Aviv Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions.

Francois Martelet, NetScientific's CEO and chairman of Vortex, said: “This partnership with BioView will allow automated identification of biomarkers expressed by CTCs collected by Vortex’s platform.”

He concluded: “This technology has potential applications in the fast-evolving field of immuno-oncology and the collaboration represents a critical step for Vortex as it moves towards the clinical market.”

View full NSCI profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.